A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

​ Conditions: TNBC; Adjuvant Therapy; Lymph Node Positive

Interventions: Drug: Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy

Sponsors: The First Affiliated Hospital with Nanjing Medical University; Qilu Pharmaceutical Co., Ltd.

Recruiting Conditions: TNBC; Adjuvant Therapy; Lymph Node Positive
Interventions: Drug: Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
Sponsors: The First Affiliated Hospital with Nanjing Medical University; Qilu Pharmaceutical Co., Ltd.
Recruiting